Authors
Bocharov A.V. 1, 3, Gruzdeva А.А.1, Popov L.V.2, Mittsiev A.K.3, 4, Lagkuev M.D.3
1 Kostroma Regional Clinical Hospital named after Korolev E.I., Kostroma
2 Pirogov National Medical and Surgical Center, Moscow
3 Republican Clinical Hospital of the Ministry of Health of the Republic of North Ossetia-Alania, Vladikavkaz
4 North-Ossetian State Medical Academy, Vladikavkaz
Abstract
Aims: to evaluate the antianginal and hemodynamic efficacy of nicorandil and metoprolol therapy in patients with microvascular angina.
Materials and methods: a comparative prospective study of the efficacy and safety of nicorandil and metoprolol in microvascular angina was carried out with the participation of 132 patients, randomly divided into two comparison groups. Patients in group 1 (n = 55) received nicorandil (daily dose 20 mg), in group 2 patients (n = 77) received metoprolol (25 or 50 mg / day). The groups did not have statistically significant differences in terms of clinical and demographic indicators.
Results: A positive hemodynamic effect was noted in both groups, a significant decrease in heart rate (5.3±4.5 beats / min, p = 0.036) and systolic blood pressure in group 2 (Δ10.1±4.2 mm Hg, p = 0.04), diastolic blood pressure in group 1 (ΔDBP 5.1±0.9 mm Hg, p = 0.047). Comparable antianginal efficacy in both groups (14.5% and 10.4%, p>0.05), therapy safety (29.1% of cases of adverse events in group 1 and 24.7% in 2, p = 0.83) against the background of a sufficiently high adherence (according to the MMAS-8 scale, 7.2±0.9 points in group 1, 7.1±0.9 in group 2, p = 0.64).
Conclusions: analysis of the clinical efficacy and safety of nicorandil and metoprolol in patients with microvascular angina pectoris showed their comparability with minor features.
Keywords: nicorandil, metoprolol, efficacy of therapy, clinically significant attacks of angina.
References
1. Stable ischemic heart disease. Clinical practice guidelines. [URL] Accessed Nov 30, 2020.
2. Soboleva GN, Fedulov VK, Samko AN, et al. Prognostic value of endothelial dysfunction in coronary and brachial arteries, and common risk factors in development of cardiovascular complications in patients with microvascular angina. Russian Journal of Cardiology. 2017; 22(3): 54-58. (In Russ). doi: 10.15829/1560-4071-2017-3-54-58.
3. Tavella R, Cutri N, Tucker G, et al. Natural history of patients with insignificant coronary artery disease. European Heart Journal. Quality of Care & Clinical Outcomes. 2016; 1;2(2): 117-24. doi: 10/1093/ehjqcco/gcv034.
4. Lanza GA, De Vita A, Kaski JC. ‘Primary’ microvascular angina: clinical characteristics, pathogenesis and management. Journal of Interventional Cardiology. 2018; 13(3): 108-111. doi: 10.15420/icr.2018.15.2.
5. Soboleva GN, Gaman SA, Ternovoy SK, et al. Disturbance of myocardial perfusion in non-obstructive coronary arteries by volume computed with adenosine triphosphate pharmacological test. REJR. 2018; 8(3): 273-8. (In Russ). doi: 10.21569/2222-2018-8-3-273-278.
6. Karpov YuA, Soboleva GN, Erpylova EA. Microvascular angina: diagnosis and treatment in 2019. Atmosphere. News of Cardiology. 2018; 4:16-27. (In Russ).
7. Patel MB, Bui LP, Kirkeeide RL, Gould KL. Imaging microvascular dysfunction and mechanisms for female-male differences in CAD. JACC. Cardiovascular Imaging. 2016; 9(4): 465-82. doi: 10.1016/j.jcmg.2016.02.003.
8. Tarasova OS, Gainullina DK. Rho-kinase as a key participant in the regulation of vascular tone in health and in vascular disorders. Arterial hypertension. 2017; 23(5): 383-394. (In Russ). doi: 10.18705/1607-419X-2017-23-5-383-394.
9. Shimokawa H., Satoh K. ATVB Plenary Lecture: translational research on rho-kinase in cardiovascular medicine. Arterioscler Thromb Vasc Biol. 2015; 35(8): 1756-69. doi:10.1161/ATVBAHA.115.305353.
10. Martsevich SYu, Kutishenko NP, Deev AD. Comparative evaluation of antianginal efficacy and safety of nicorandil on background of basic therapy with beta-blockers in patients with coronary heart disease with stable angina. Cardiology. 2016; 56(10): 30-34. (In Russ).
11. Voronina VP, Martsevich SYu, Kutishenko NP, Deev AD. Assessment of antiischemic and antianginal effects of nicorandil by treadmill test, under the framework of Kvazar study. Russian Journal of Cardiology. 2017; 22(3): 97-103. (In Russ). doi: 10.15829/1560-4071-2017-3-97-103.
12. Martsevich SYu, Kutishenko NP, Deev AD. The assessment of nicorandil effect on the quality of life in patients with stable angina in the KVAZAR study. Rational pharmacotherapy in Cardiology. 2016; 12(6): 654-660. (In Russ). doi: 10.20996/ 1819-6446-2016-12-6-654-660.
13. Federal guidelines for the use of medicines (formulary system). Issue XVIII. Chuchalin AG, Khokhlov AL, editors. Moscow: Vidoks; 2017. (In Russ).
14. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomized trials in the context of expectations from prospective epidemiological studies. BMJ. 2009; 338: b1665. doi:10.1136/bmj.b1665.
15. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology. J Hypertens. 2013; 31(7): 1281-357. doi: 10.1097/01.hjh.0000431740.32696.cc.
16. Arterial hypertension in adults. Clinical practice guidelines [cited by Nov 11, 2020]. [URL] Accessed Nov 30, 2020. (In Russ).
17. Agafonova GA, Babich AE, Tumanova KR, Klimenko AA. Metoprolol in the pharmacotherapy of ischemic heart disease and concomitant pathology. Attending Doctor. 2017. (In Russ).
18. Instructions for the medical use of Coronel. [URL] Accessed Nov 30, 2020. (In Russ).
